Edition:
United Kingdom

Pharmaceuticals

Page 1

Hutchison China MediTech Announces Start Of Clinical Trial In China

Friday, 23 Aug 2019

Aug 23 (Reuters) - Hutchison China MediTech Ltd ::START OF CLINICAL TRIAL IN CHINA.START OF CLINICAL TRIAL IN CHINA.INITIATED PHASE I STUDY OF HMPL-523, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA.FIRST ITP PATIENT WAS DOSED ON AUGUST 12, 2019 IN CHINA.

GSK Says DREAMM-2 Study For Multiple Myeloma Met Main Goal

Friday, 23 Aug 2019

Aug 23 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK - POSITIVE RESULTS FROM PIVOTAL DREAMM-2 STUDY.GLAXOSMITHKLINE PLC - BELANTAMAB MAFODOTIN (GSK2857916) ON TRACK FOR REGULATORY SUBMISSION BY END OF 2019.GLAXOSMITHKLINE PLC - ANNOUNCES POSITIVE HEADLINE RESULTS FROM PIVOTAL DREAMM-2 STUDY FOR MULTIPLE MYELOMA.GSK- TWO-ARM STUDY MET PRIMARY OBJECTIVE AND DEMONSTRATED CLINICALLY MEANINGFUL OVERALL RESPONSE RATE WITH BELANTAMAB MAFODOTIN IN PATIENT POPULATION.GLAXOSMITHKLINE PLC - DATA FROM DREAMM-2 STUDY WILL BE BASIS FOR REGULATORY FILINGS STARTING LATER THIS YEAR.GLAXOSMITHKLINE PLC - SAFETY AND EFFICACY RESULTS FROM DREAMM-2 STUDY WILL BE SUBMITTED FOR PRESENTATION AT AN UPCOMING SCIENTIFIC MEETING.GLAXOSMITHKLINE PLC - SAFETY AND TOLERABILITY PROFILE WAS CONSISTENT WITH THAT OBSERVED IN DREAMM-1, FIRST TIME IN HUMAN STUDY OF BELANTAMAB MAFODOTIN.

Vicore Pharma Q2 Operating Loss Widens To SEK 24.8 Mln

Friday, 23 Aug 2019

Aug 23 (Reuters) - Vicore Pharma Holding AB ::INTERIM REPORT APRIL-JUNE 2019.Q2 OPERATING LOSS WAS -24.8 MSEK (-9.6).

Navamedic Q2 EBITDA Down At NOK 0.9 Million

Friday, 23 Aug 2019

Aug 23 (Reuters) - Navamedic ASA ::REPORTED REVENUES OF NOK 47.2 MILLION IN Q2 OF 2019, UP 4.4% FROM SAME PERIOD IN 2018.Q2 EBITDA CAME IN AT NOK 0.9 MILLION (NOK 5.6 MILLION IN Q2 OF 2018).Q2 GROSS MARGIN WAS 34.4% (34.9%).LOWER EBITDA IN Q2 MAINLY DUE TO INCREASED STRATEGIC PROJECT COST OF MNOK 2.6 AND INCREASED RESOURCES AND FOCUS ON BUSINESS DEVELOPMENT.POSITIVE Q2 REVENUE DEVELOPMENT, DRIVEN BY STRONG PERFORMANCE IN OBESITY AND MEDICAL NUTRITION.

Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

Thursday, 22 Aug 2019

Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW.CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE I/III IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF OVERALL SURVIVAL.

Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

Thursday, 22 Aug 2019

Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW.CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE I/III IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF OVERALL SURVIVAL.

Lifespot Capital 2018 Net Loss At About EUR 1.26 Mln

Thursday, 22 Aug 2019

Aug 22 (Reuters) - Lifespot Capital AG ::NET LOSS FOR 2018 WAS APPROXIMATELY EUR 1.26 MILLION COMPARED TO EUR 1.25 MILLION IN THE PREVIOUS YEAR.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary